Covid19
Conditions
Keywords
SARS-CoV-2, Immunologic biomarkers, Vaccine
Brief summary
Prospective study to describe the immunological, metabolic and serologic profile in the acute and post acute phases of Coronavirus disease (COVID-19)
Interventions
PROCEDUREBlood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.
40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
PROCEDUREBlood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers
40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
Sponsors
Poitiers University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
for patients: * adult patient * Patient with Covid-19 confirmed by RT-PCR, supported by Poitiers hospital * Patient came for RT-PCR test at the drive of the hospital, or hospitalised in one of the Covid-19 departments of the Poitiers hospital (geriatry, infectious and tropical diseases, medical resuscitation and continuous care unit) * informed consent signed by the patient or a trusted or immediate person after clear and loyal information on the study
Exclusion criteria
for patients: * minor patient * patient having had syptoms for more than 8 days * patient already enrolled in another study regarding immunomodulators * patient not benefiting from a Social Security scheme or not benefiting from it through a third party * patient benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adult under legal protection Inclusion Criteria for volunteers: * adult patient * subject wishing to be vaccinated with anti-COVID-19 BioNTech Pfizer vaccine * informed consent signed by the volunteer after clear and loyal information on the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neutralizing antibodies | Day 8 following the first SARS-CoV-2 symptoms for patients | Serum titre of neutralizing antibodies |
| T CD8 lymphocytes | Day 8 following the first SARS-CoV-2 symptoms for patients | Blood concentration of T CD8 lymphocytes |
| Inflammatory markers | Day 8 following the first SARS-CoV-2 symptoms for patients | Blood levels of pro-inflammatory cytokines |
| Metabolic markers | Day 8 following the first SARS-CoV-2 symptoms for patients | Blood concentration of glucosidases |
Countries
France
Outcome results
None listed